✦ LIBER ✦

Rationale for the use of clodronate in osteoporosis

✍ Scribed by J. A. Kanis; E. V. McCloskey; P. Sirtori; S. Khan; D. Fern; K. Eyres; J. Aaron; M. N. C. Beneton

Publisher: Springer-Verlag
Year: 1993
Tongue: English
Weight: 820 KB
Volume: 3
Category: Article
ISSN: 0937-941X
DOI: 10.1007/bf01623223

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clodronate (Bonefos®) in the management

Clodronate (Bonefos®) in the management of glucocorticoid-induced osteoporosis

✍ H. Puolijoki; J. Herrala; K. Liippo; M. Raitio; O. Impivaara; M. M. Nieminen; E. 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 130 KB

Clodronate treatment of established oste

Clodronate treatment of established osteoporosis in ovariectomized rats

✍ R. Hannuniemi; K. Kippo; Z. Peng; L. Laurén; P. Kuutamo; R. Sellman; H. K. Väänä 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 136 KB

Rationale for active vitamin D analogue

Rationale for active vitamin D analogue therapy in osteoporosis

✍ D. J. Baylink; K. Akesson 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 157 KB

Rationale for active vitamin D and analo

Rationale for active vitamin D and analogs in the treatment of osteoporosis

✍ Yasuho Nishii 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

## Abstract In 1981, Chugai Pharmaceutical succeeded in marketing alfacalcidol, a prodrug of calcitriol, as a therapeutic agent for renal osteodystrophy. In 1983, Chugai succeeded in extending the application of alfacalcidol to the treatment of osteoporosis as well. Clinicians in Japan have accepte

Quantitative ultrasound of bone and clod

Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis

✍ Pietra Pennisi; Giuseppe Pizzarelli; Massimo Spina; Stefania Riccobene; Carmelo 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 245 KB

Rationale for active vitamin D analog th

Rationale for active vitamin D analog therapy in senile osteoporosis

✍ K. Åkesson; K. -H. W. Lau; D. J. Baylink 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 651 KB